BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, TD Cowen Analyst Says

Key Points

• TD Cowen raised BridgeBio Pharma’s price target from $95 to $110 and maintained a “buy” rating, implying 31.09% upside from the prior close. The broader analyst consensus is “Moderate Buy,” with a $99.28 target.
• BridgeBio’s latest quarter showed revenue of $243.7 million, up 120.4% year over year and above estimates, but its $0.78-per-share loss was wider than analysts expected.
• Shares fell 0.9% to $83.92, while insiders sold approximately $29.9 million of stock over the past 90 days. Investors are also watching potential pipeline catalysts, including regulatory decisions and late-stage trial results.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price objective hoisted by investment analysts at TD Cowen from $95.00 to $110.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a "buy" rating on the stock. TD Cowen's price target points to a potential upside of 31.09% from the stock's previous close.

BBIO has been the topic of several other reports. Morgan Stanley upped their price objective on shares of BridgeBio Pharma from $94.00 to $98.00 and gave the company an "overweight" rating in a report on Thursday, May 28th. Wells Fargo & Company boosted their price target on shares of BridgeBio Pharma from $98.00 to $102.00 and gave the stock an "overweight" rating in a report on Tuesday. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $110.00 to $120.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $110.00 target price on shares of BridgeBio Pharma in a report on Tuesday. Finally, Raymond James Financial cut BridgeBio Pharma from an "outperform" rating to a "market perform" rating in a research note on Tuesday, May 26th. Nineteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BridgeBio Pharma currently has an average rating of "Moderate Buy" and a consensus price target of $99.28.

BridgeBio Pharma Stock Down 0.9%

Shares of NASDAQ BBIO traded down $0.76 during midday trading on Tuesday, reaching $83.92. 990,910 shares of the company's stock traded hands, compared to its average volume of 2,991,225. The company has a market cap of $16.40 billion, a price-to-earnings ratio of -22.45 and a beta of 0.96. BridgeBio Pharma has a one year low of $46.81 and a one year high of $93.42. The stock's 50 day simple moving average is $76.07 and its 200-day simple moving average is $73.03.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.20). The firm had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. During the same quarter in the previous year, the firm posted ($0.95) earnings per share. The company's quarterly revenue was up 120.4% on a year-over-year basis. Equities analysts predict that BridgeBio Pharma will post -2.31 EPS for the current fiscal year.

Insider Activity at BridgeBio Pharma

In other news, CAO Maricel Apuli sold 2,000 shares of the company's stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $80.06, for a total transaction of $160,120.00. Following the transaction, the chief accounting officer directly owned 127,401 shares of the company's stock, valued at $10,199,724.06. This represents a 1.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Andrea Ellis sold 17,167 shares of the stock in a transaction dated Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the completion of the transaction, the director directly owned 22,579 shares of the company's stock, valued at approximately $1,896,636. This trade represents a 43.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 392,117 shares of company stock worth $29,934,700. 14.23% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BridgeBio Pharma

A number of hedge funds have recently made changes to their positions in BBIO. Brooklands Fund Management Ltd acquired a new position in shares of BridgeBio Pharma in the fourth quarter worth about $210,348,000. Price T Rowe Associates Inc. MD grew its holdings in BridgeBio Pharma by 144.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company's stock worth $292,862,000 after buying an additional 2,261,181 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of BridgeBio Pharma by 25.8% during the fourth quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company's stock valued at $841,349,000 after purchasing an additional 2,259,378 shares during the period. Norges Bank bought a new stake in shares of BridgeBio Pharma during the 4th quarter worth about $116,802,000. Finally, Wellington Management Group LLP lifted its position in BridgeBio Pharma by 130.4% in the fourth quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company's stock worth $179,654,000 after purchasing an additional 1,329,537 shares during the period. Hedge funds and other institutional investors own 99.85% of the company's stock.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Analysts raise targets: Piper Sandler increased its price target from $111 to $115 and maintained an “overweight” rating. Wells Fargo also raised its target, from $98 to $102, while keeping an “overweight” rating. The revisions imply substantial potential upside and reflect continued confidence in BridgeBio’s development pipeline. Benzinga analyst price-target updates
• Positive Sentiment: Pipeline catalysts could drive sentiment: BridgeBio is listed among biotech companies with major second-half 2026 catalysts, including potential regulatory decisions and late-stage clinical-trial readouts. Positive data or approvals could provide important valuation catalysts for BBIO. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Neutral Sentiment: Revenue growth was strong: Second-quarter revenue reached $243.7 million, beating the $220.9 million consensus estimate and increasing 120.4% from the prior year. The improvement suggests commercial and partnered-product activity is expanding, although investors remain focused on the company’s path toward profitability. BridgeBio Pharma Reports Q2 Loss, Tops Revenue Estimates
• Negative Sentiment: Quarterly loss exceeded expectations: BridgeBio reported a second-quarter loss of $0.78 per share, wider than the $0.58 analyst consensus, despite improving from a $0.95 loss per share a year earlier. The earnings miss may limit the stock’s near-term upside and reinforce concerns about ongoing cash needs and operating costs. BridgeBio Pharma Q2 Earnings Results and Conference Call

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source